Clinical Trial Update: OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial update for MS1819 in exocrine pancreatic insufficiency due to cystic fibrosis; trial completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Exocrine Pancreatic Insufficiency

Drugs mentioned

• MS1819 (MS1819)

Snippet

Sponsor: Entero Therapeutics | Conditions: Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF) | Phase 2 | Status: COMPLETED | Results posted: 2022-06-06